Description: The investment seeks to track the investment results (before fees and expenses) of the Nasdaq Biotechnology Index ®. The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 87.99 | 0.00 | 87.99 |
| Stock non-US | 12.03 | 0.00 | 12.03 |
| Cash | 0.00 | 0.02 | -0.02 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 99.57 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 88.85 | 92.60 |
| United Kingdom | 5.14 | 1.65 |
| Europe Developed | 3.82 | 4.28 |
| Asia Emerging | 2.09 | 0.82 |
| Asia Developed | 0.10 | 0.00 |
| Japan | 0.00 | 0.54 |
| Australasia | 0.00 | 0.11 |
| Africa/Middle East | 0.00 | 0.02 |